Volume 16 - Issue 8 - August, 2004
National Healthy Leg Day Scheduled
- 7/31/2004
- 0 Comments
- 1581 reads
Sigvaris Inc. will hold seminars to celebrate the first National Healthy Leg Day. Scheduled for October 15 in Atlanta, Georgia, the event intends to provide education on risk factors for vein disorders. According to the National Women’s Health Information Center, 60 percent of American men and women suffer from some form of vein disorder, most commonly varicose veins. Another venous disorder, deep vein thrombosis (DVT), a blood clot that forms in a deep vein, claims up to 200,000 people yearly in the United States—more than AIDS and breast cancer combined.
National Healthy Leg Day will
Pharmaceutical Product for Wound Debriding Now Available Nationwide as a Spray
- 7/31/2004
- 0 Comments
- 2119 reads
HEALTHPOINT Ltd. announces that ACCUZYME® (Papain, Urea) Ointment, its popular pharmaceutical product for wound debriding, is now available in a new pump-spray delivery system, ACCUZYME Spray, on which a patent application is pending.
ACCUZYME Spray is HEALTHPOINT’s second product to feature the unique, nonaerosol, spray delivery. PANAFIL® (Papain, Urea, Chlorophyllin Copper Complex Sodium) Spray arrived on the market in February, and the wound healing, debriding, and deodorizing product has quickly gained a following.
Until now, ACCUZYME has been available only as an ointment that re
Evidence Corner
- 7/31/2004
- 0 Comments
- 3189 reads
D ear Readers: Wound exudate is a perennial challenge to professionals and caregivers. It may also provide clues to wound vitality and may play a role in healing or wound deterioration. Clinically it has been shown to contain natural growth factors that trigger cell proliferation1 and enzymes that autolytically debride necrotic tissue and fibrin2. This Evidence Corner focuses on a versatile family of exudate components, called matrix metalloproteinases (MMPs). They are natural proteolytic enzymes deemed essential to tissue regeneration and remodeling3.
Staphylococcus aureus is Associated with High Microbial Load in Chronic Wounds
- 7/31/2004
- 0 Comments
- 5221 reads
Abstract: The purpose of this study was to describe the association of Staphylococcus aureus with clinical and microbiological indicators of localized infection in a sample of chronic wounds. Sixty-six subjects with chronic wounds were assessed for signs and symptoms of localized infection, and viable wound tissue specimens were obtained for quantitative microbiological analyses. The study wounds were then grouped according to whether or not they contained S. aureus and statistically compared for differences in the expression of clinical signs of infection, microbial load (i.e., number
Skin Graft Donor Site and Use of Polydeoxyribonucleotide as a Treatment for Skin Regeneration: A Randomized, Controlled, Double-
- 7/31/2004
- 0 Comments
- 4690 reads
Abstract: The effect of polydeoxyribonucleotide (PDRN) vs. placebo on the wound healing process in patients undergoing skin grafts during reconstructive surgery was evaluated. In this double-blind, placebo-controlled study, 58 patients of both sexes subjected to skin grafts were studied and randomly allocated in two homogeneous groups treated with standard therapy plus PDRN (3mL ampoule contains PDRN mg. 5.625) or placebo. PDRN or placebo were administered by intramuscular injection once daily for 10 days and by perilesional infiltration at Days 1 and 5, postoperatively. Checks were car
The Use of Negative Pressure Wound Therapy on Diabetic Foot Ulcers: A Preliminary Controlled Trial
- 7/31/2004
- 0 Comments
- 6269 reads
Abstract: The purpose of this clinical study was to investigate the effects of negative pressure wound therapy (NPWT) on the healing of diabetic foot ulcers and to compare this dressing with traditional moist gauze dressing as a treatment used prior to other wound closure techniques, such as flaps or grafts. Twenty-four diabetic patients were randomly divided into two groups: NPWT group and control group. Initially, the mean surface area of the diabetic wounds was 109cm2 in the NPWT group and 94.8cm2 in the control group. The mean duration of wound care (until the
Development of Foot Drop Following Compression Therapy
- 7/31/2004
- 0 Comments
- 3767 reads
Abstract: Compression therapy is the mainstay of treatment of venous ulceration. We have observed foot drop, due to compression of the common peroneal nerve on the fibular neck, related to compression therapy. Specifically, we believe this complication arose due to a reduction in the usual amount of padding employed on account of the unusally hot weather at the time. We are unaware of a precedent and seek to alert wound care providers to this potential hazard.
G raduated compression bandaging has been shown by meta-analysis of randomized controlled trials to be the most effective t
Celleration, Inc. Receives FDA Clearance for MIST Therapy System 5.0™ Wound Treatment Device
- 7/31/2004
- 0 Comments
- 2083 reads
Celleration, Inc. announces that it has received clearance from the US Food and Drug Administration (FDA) to market its MIST Therapy System 5.0™. The clearance was obtained through the FDA de novo process, a part of the FDA Modernization Act of 1997 (FDAMA). The company believes that this clearance through the de novo process may provide potential market advantages. MIST Therapy is indicated for wound cleaning and maintenance debridement of wounds containing yellow slough, fibrin, tissue exudate, or bacteria, the removal of which is important for the healing process. This indication allows
New Program Provides a Network of Information and Products that Enhance Skin Care and Wound Prevention
- 7/31/2004
- 0 Comments
- 1299 reads
Swiss-American Products, Inc., a Dallas-based manufacturer of specialty skin and wound care products, is launching an innovative program designed to give healthcare providers additional resources and knowledge related to skin care and wound prevention and treatment. Swiss-American developed the Collective Learning Education And Resources (CLEAR ChoiceSM) program to help assisted living facilities, hospices, home healthcare groups, independent living facilities, pharmacies, and intermediate and long-term care facilities improve their ability to meet the clinical needs of their patients and man
Posey Introduces Upgraded Knitted Heel/Elbow Protectors
- 7/31/2004
- 0 Comments
- 1723 reads
The Posey Company introduces a new line of Knitted Heel and Elbow Protectors (Cat. No. 6224) for its wound prevention line. The Heel and Elbow Protectors are comfortable sock-like coverings that provide comfort and help reduce tissue interface pressure in low-risk patients.
The new Heel and Elbow Protectors are made from a flexible stretch weave material with a cushioned foam pad sewn to the inside. The expandable sleeve is easy to remove and helps keep extremities warm without restricting blood circulation. The highly cushioned noncotton yarn helps minimize friction and shearing. The new H
- « Previous
- | Page 1 of 2 |
- Next »
_sm.jpg)
